Overview

Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Hydrochlorothiazide
Valsartan